These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 8825132)

  • 21. CA 15-3 in human breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
    Caponigro F; Iaffaioli RV; Pagliarulo C; De Placido S; Frasci G; Ungaro B; Matano E; Bianco AR
    Int J Biol Markers; 1990; 5(2):73-6. PubMed ID: 2283480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA.
    Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Winkel P; Mouridsen HT; Dombernowsky P
    Ann Oncol; 1993 Dec; 4(10):861-9. PubMed ID: 8117606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CA 549 and SP2 in postoperative breast cancer patients. Comparison with CA 15.3, CEA and TPA.
    Torres M; Pacheco C; Valverde A; Rebollo AC; Moral A; Vallejo JA; Mateo A
    Int J Biol Markers; 1995; 10(2):94-9. PubMed ID: 7561245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen.
    Safi F; Kohler I; Röttinger E; Beger H
    Cancer; 1991 Aug; 68(3):574-82. PubMed ID: 2065278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
    Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
    Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival.
    Nicolini A; Ferrari P; Duffy MJ; Antonelli A; Rossi G; Metelli MR; Fulceri F; Anselmi L; Conte M; Berti P; Miccoli P
    Arch Surg; 2010 Dec; 145(12):1177-83. PubMed ID: 21173292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer.
    Jing JX; Wang Y; Xu XQ; Sun T; Tian BG; Du LL; Zhao XW; Han CZ
    Asian Pac J Cancer Prev; 2014; 15(23):10267-72. PubMed ID: 25556459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients.
    Bahrami A; Mortazavizadeh MR; Yazdi MF; Chamani M
    East Mediterr Health J; 2012 Oct; 18(10):1055-9. PubMed ID: 23301361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of CEA, TPA, and Ca 19-9 in the early detection of localized and diffuse recurrent rectal cancer.
    Barillari P; Bolognese A; Chirletti P; Cardi M; Sammartino P; Stipa V
    Dis Colon Rectum; 1992 May; 35(5):471-6. PubMed ID: 1568399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Tumor markers in breast cancer: on the diagnostic value of serum determinations in clinical freedom from tumor and manifest disease].
    Günczler P; Ogris E; Maca S; Danmayr E
    Onkologie; 1989 Oct; 12(5):209-14. PubMed ID: 2685686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3.
    Molina R; Jo J; Zanón G; Filella X; Farrus B; Muñoz M; Latre ML; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta AM
    Br J Cancer; 1996 Oct; 74(7):1126-31. PubMed ID: 8855986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The tumor markers TPA and CEA in the after care of breast cancer].
    Beaufort F; Fueger GF; Steiner H
    Wien Med Wochenschr; 1985 Feb; 135(4):85-8. PubMed ID: 2986366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
    Chen C; Chen Q; Dong Y; Liu X
    Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical importance of determination of tumor markers during follow-up in breast carcinoma].
    Fínek J; Holubec L; Topolcan O; Pikner R; Sůvová B; Treska V
    Cas Lek Cesk; 2004; 143(3):174-7. PubMed ID: 15134036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis.
    Arslan N; Serdar M; Deveci S; Ozturk B; Narin Y; Ilgan S; Ozturk E; Ozguven MA
    Ann Nucl Med; 2000 Oct; 14(5):395-9. PubMed ID: 11108173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CEA, TPA, CA 19-9, SCC and CYFRA at diagnosis and in the follow-up of anal canal tumors.
    Indinnimeo M; Reale MG; Cicchini C; Stazi A; Fiori E; Izzo P
    Int Surg; 1997; 82(3):275-9. PubMed ID: 9372374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical utility of tumour marker velocity of cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in breast cancer surveillance.
    Hing JX; Mok CW; Tan PT; Sudhakar SS; Seah CM; Lee WP; Tan SM
    Breast; 2020 Aug; 52():95-101. PubMed ID: 32485607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of TPS and TPA in the Diagnostics of Distant Metastases.
    Kucera R; Topolcan O; Fiala O; Kinkorova J; Treska V; Zedníková I; Slouka D; Simanek V; Safanda M; Babuska V
    Anticancer Res; 2016 Feb; 36(2):773-7. PubMed ID: 26851038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tissue polypeptide antigen and carcinoembryonic antigen as tumor markers in lung cancer.
    Lee YC; Yang PC; Kuo SH; Luh KT
    J Formos Med Assoc; 1991 Jul; 90(7):631-6. PubMed ID: 1681012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease.
    Bottini A; Berruti A; Tampellini M; Morrica B; Brunelli A; Gnocchi E; Brizzi MP; Aguggini S; Fara E; Alquati P; Dogliotti L
    Tumour Biol; 1997; 18(5):301-10. PubMed ID: 9276030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.